What is a brain tumour and what are the typical symptoms?
A brain tumour is an abnormal growth of cells within the brain tissue or surrounding membranes, known as the meninges. Tumours can be primary, originating directly in cranial cells, or secondary (metastatic), spreading from primary cancers located elsewhere in the body. Primary tumours include benign lesions such as meningiomas, acoustic neuromas, and pituitary adenomas, as well as malignant forms such as glioblastomas, astrocytomas, and oligodendrogliomas. Benign tumours do not spread to distant organs, but their growth inside the rigid cranial cavity can still compress vital neurological structures.
Symptoms arise because the lesion occupies space and increases intracranial pressure, or because it disrupts specific neurological pathways. Common signs include:
- Persistent headaches: Often worse in the morning, waking you from sleep, or intensifying during coughing or bending down.
- Seizures: New onset seizures in an adult with no prior history of epilepsy.
- Neurological deficits: Weakness, numbness, or loss of sensation on one side of the face or body.
- Visual and sensory changes: Blurry vision, loss of peripheral vision, or progressive hearing loss.
- Cognitive or personality shifts: Memory issues, confusion, speech difficulties, or subtle personality changes.
- Nausea and vomiting: Unexplained vomiting, frequently accompanied by dizziness or balance instability.
How a brain tumour is diagnosed
Accurate diagnosis requires comprehensive neuroimaging and pathology. When presenting to a hospital in Turkey, your medical team will verify previous tests or conduct new high-resolution evaluations to determine the precise size, anatomical boundary, and vascular supply of the lesion.
Initial diagnostic assessments arranged through check-ups and diagnostics departments typically include:
- Magnetic Resonance Imaging (MRI): High-resolution 3 Tesla multiparametric MRI with intravenous gadolinium contrast remains the primary diagnostic tool. Functional MRI (fMRI) and diffusion tensor tractography may map motor and language pathways adjacent to the lesion.
- Computed Tomography (CT): Non-contrast or contrast CT scans evaluate acute bleeding, calcifications, and bony erosion around the skull base.
- PET or MR Spectroscopy: Evaluates tissue metabolism to differentiate active tumour recurrence from radiation necrosis.
- Histopathology and molecular profiling: After surgical resection or stereotactic biopsy, tissue samples undergo molecular testing (such as IDH mutation, MGMT promoter methylation, and 1p/19q codeletion) to refine the diagnosis and guide ongoing care.
Before travelling, patients must compile all diagnostic records. Bring original DICOM imaging files on a USB drive or disc rather than paper printouts, as neurosurgeons require raw image slices for 3D surgical neuronavigation. Also gather official radiology reports, previous biopsy slides or paraffin blocks, a full medication history, and recent blood tests.
Treatment options and when each is used
Brain tumour management depends on tumour histology, grade, anatomic location, patient age, and baseline functional status. Modern approaches rely on combined modalities coordinated between neurosurgery and oncology specialists.
| Option |
Typically used when |
Things to know |
| Microsurgical resection |
Surgically accessible tumours causing mass effect or where tissue diagnosis and pressure relief are critical. |
Employs intraoperative MRI, neuro-navigation, cortical mapping, or awake craniotomy to protect functional speech and motor areas. |
| Stereotactic radiosurgery |
Small, well-defined tumours, skull base lesions, deep-seated brain metastases, or residual benign tumours. |
Delivers concentrated radiation beams via Gamma Knife or CyberKnife without open craniotomy; performed on an outpatient basis. |
| Fractionated radiotherapy |
High-grade malignant tumours, infiltrative margins, or post-surgical beds where microscopic cells remain. |
Administered in divided daily doses over several weeks to eradicate residual malignant cells while preserving healthy brain tissue. |
| Chemotherapy and targeted drugs |
Malignant gliomas, primary central nervous system lymphoma, or specific systemic metastatic tumours. |
Includes oral agents such as temozolomide that cross the blood-brain barrier; dosing depends on molecular markers. |
| Endoscopic transsphenoidal surgery |
Pituitary adenomas and select skull base lesions accessible through the nasal cavity. |
Performed via the nasal passage with minimal external incisions, often evaluated alongside endocrinology specialists. |
Planning treatment in Turkey
Medical travel for neurosurgical care requires careful preparation. International departments arrange a preliminary multidisciplinary tumour board review using your shared digital imaging and clinical summaries. The medical team will assess whether the tumour is operable, outline proposed interventions, and clarify anticipated risks before you leave home.
Hospital stays generally range from 3 to 7 days for uncomplicated craniotomy, or 1 to 2 days for stereotactic radiosurgery. However, international patients should plan to remain in Turkey for at least 14 to 21 days following open brain surgery. This allows time for post-operative imaging, suture or staple removal, monitoring for cerebrospinal fluid leaks or infection, and initial physical therapy supported by rehabilitation teams. Decisions regarding fitness to fly depend on intracranial air absorption and wound healing; you must receive explicit written clearance from your neurosurgeon before booking a flight home. Your treating team will prepare an English-language discharge summary, operative report, and post-operative scans to facilitate ongoing care with your local physician.
When travel is not advisable and urgent warning signs
International air travel involves changes in cabin atmospheric pressure that can expand trapped air or worsen cerebral oedema (brain swelling). Travel is strictly not advisable if you have severe intracranial hypertension, unmanaged hydrocephalus, or active midline shift on imaging.
Seek immediate medical emergency attention at your nearest local hospital if you or a family member experience:
- Sudden loss of consciousness, unresponsiveness, or profound lethargy.
- A severe, explosive headache unlike any previously experienced.
- New or worsening status epilepticus (repeated, prolonged seizures without regaining consciousness).
- Acute onset of paralysis, facial droop, or inability to speak or swallow.
- Unequal pupil sizes or sudden total loss of vision.
These signs suggest acute intracranial herniation or haemorrhage that requires immediate local stabilisation rather than long-distance travel.
